{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"146-485-473-482-461","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"146-485-473-482-461","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11619,"type":"PATENT","title":"Georgia Institute of Technology - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6421,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8294,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: georg* inst*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 6058
Search Applicants and Owners separately: georg* inst*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 6058
a. contacting one or more cells with a plurality of noble metal nanoparticles, wherein the noble metal nanoparticles are conjugated to a binding moiety specific for the target polypeptide and have surface resonance scattering spectrum;\n
b. exposing the noble metal nanoparticles with light having a wavelength within the wavelength rage of the surface plasmon resonance scattering or of the surface resonance plasmon absorption maximum of the nanoparticles; and\n
c. detecting a bright field or dark field image of the cells, wherein an image of the cells is indicative of cells expressing the target polypeptide."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, further comprising the step of exposing the noble metal nanoparticles with an amount of light effective to generate heat from the noble metal nanoparticles in amount effective to damage cells or tissue adjacent to or in contact with the nanoparticles."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the nanoparticles consist essentially of a solid noble metal or solid noble metal alloy."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3, wherein the noble metal nanoparticles comprise a stabilizer."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the binding moiety is coupled to the stabilizer or directly to the nanoparticle."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the stabilizer comprises polyethylene glycol (PEG), poly(styrenesulfonate), cetyl trimethyl ammonium bromide, or a combination thereof."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the target substance is a biomarker for a disease or pathology."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the noble metal nanoparticles comprise an aspect ratio of about 1."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the plasmon resonance absorption maximum differs when the binding moiety is unbound or bound to the target substance."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the target substance comprises an intracellular or extracellular polypeptide or fragment thereof."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the noble metal nanoparticle comprises silver, gold, or a combination thereof."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the binding moiety comprises an antibody, aptamer, carbohydrate, polypeptide, lipid, or nucleic acid."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method for determining when a probe is bound to a target comprising:\n
a. contacting a sample with the probe, wherein the probe comprises a noble metal nanoparticle conjugated to a binding moiety specific for the target, and wherein the unbound probe has a first resonance plasmon absorption maximum;\n
b. exposing the probe to electromagnetic radiation; and\n
c. detecting a second resonance plasmon absorption maximum from the probe contacting the sample, wherein a detectable difference between the first resonance plasmon absorption maximum and the second resonance plasmon absorption spectrum indicates the probe is bound to the target."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating a pathology, comprising:\n
a. delivering one or more noble metal nanoparticles coupled to a binding moiety that specifically binds to a target substance expressed by the pathology to a region of a host having or suspected of having the pathology; and\n
b. exposing the one or more noble metal nanoparticles to light having a wavelength within the nanoparticles' surface plasmon absorption spectrum and at an intensity of about 50% or less than the intensity effective to kill healthy cells unbound by the noble metal nanoparticles; wherein the one or more noble metal nanoparticles absorbs the light and converts the absorbed light to heat."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the region is within about 5 mm of an exterior surface of the host."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["17.-23. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the noble metal nanoparticles consist essentially of gold or silver metal particles having an aspect ratio of about 2.7 to about 10."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["25.-27. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the target substance is selected from the group consisting of epidermal growth factor receptor, transferrin receptor, platelet-derived growth factor receptor, Erb-B2, CD 19, CD20, CD45, CD52, Ep-CAM, alpha ([alpha])-fetoprotein, carcinoembryonic antigen peptide-1, caspase-8, CDC27, CDK4, carcino-embryonic antigen, calcium-activated chloride channel-2, cyclophilin B, differentiation antigen melanoma, elongation factor 2, Ephrin type-A receptor 2, 3, Fibroblast growth factor-5, fibronectin, glycoprotein 250, G antigen, N-acetylglucosaminyltransferase V, glycoprotein 100 kD, helicase antigen, human epidermal receptor-2/neurological, heat shock protein 70-2 mutated, human signet ring tumor-2, human telomerase reverse transcriptase, intestinal carboxyl esterase, interleukin 13 receptor [alpha]2 chain, [beta]-D-galactosidase 2-[alpha]-L-fucosyltransferase, melanoma antigen, melanoma antigen recognized by T cells-1/Melanoma antigen A, melanocortin 1 receptor, macrophage colony-stimulating factor, mucin 1, 2, melanoma ubiquitous mutated 1, 2, 3, New York-esophageous 1, ocular albinism type 1 protein, O-linked N-acetyl glucosamine transferase gene, protein 15, promyelocytic leukemia/retinoic acid receptor [alpha], prostate-specific antigen, prostate-specific membrane antigen, receptor-type protein-tyrosinephosphatase kappa, renal antigen, renal ubiquitous 1, 2, sarcoma antigen, squamous antigen rejecting tumor 1, 2, 3, synovial sarcoma, Survivin-2B, synaptotagmin I/synovial sarcoma, X fusion protein, translocation Ets-family leukemia/acute myeloid leukemia 1, transforming growth factor [beta] receptor 2, triosephosphate isomerase, taxol resistant associated protein 3, testin-related gene, tyrosinase related protein 1, and tyrosinase related protein 2."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["29.-33. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38 wherein the amount of light effective to damage cells expressing the target substance is about 5 to about 80% of the amount of light needed to damage cells not expressing the target substance and having a plurality of noble metal nanoparticles."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["35.-37. (canceled)"],"number":-1,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating cancer comprising:\n
administering a plurality of solid noble metal nanoparticles comprising a surface plasmon resonance absorption maximum greater than about 600 nm wherein the solid noble metal nanoparticles are targeted to one or more cancer cells and specifically associate with one or more cancer cells; and\n
exposing the plurality of noble metal nanoparticles with light comprising the surface plasmon resonance absorption maximum of the solid noble metal nanoparticles in an amount effective to generate an amount of heat from the nanoparticles effective to damage the targeted cancer cells associated with the solid noble metal nanoparticles."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the solid noble metal nanoparticles are targeted to cancer cells via one or more binding moieties conjugated to the solid noble metal nanoparticles."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the solid noble metal nanoparticles are targeted to the cancer cells via a polymeric coating."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the polymeric coating comprises polyethylene glycol."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["An antibody comprising a solid noble metal nanorod having an aspect ratio of about 2.5 to about 10, or an antigen binding fragment thereof, wherein the solid metal nanorod absorbs light in the near infrared."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The antibody of claim 41, wherein the solid noble metal nanorod consists essentially of a noble metal optionally coated with a polymer."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["The antibody of claim 43, wherein the polymer comprises polyethylene glycol, cetyltrimethylammonium bromide, poly(styrenesulfonate), or a combination thereof."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["(canceled)"],"number":45,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}